CRL

188.68

3.40% 6.20

After Hours: 177.58 -11.10 -5.88%

Charles River Laboratories International Inc (CRL)

Overview News Price History Option Chain Financials Discussions Forecast

Charles River Laboratories International Inc stock is traded at $188.68, with a volume of 990.33K. It is up +3.40% in the last 24 hours and down -1.08% over the past month.

Previous Close:

$182.48

Open:

$180.89

24h Volume:

990.33K

Relative Volume:

1.34

Market Cap:

$10.63B

Revenue:

$4.08B

Net Income/Loss:

$431.79M

P/E Ratio:

20.01

EPS:

9.43

Net Cash Flow:

$486.92M

1W Performance:

+2.54%

1M Performance:

-1.08%

6M Performance:

-19.18%

1Y Performance:

+3.72%

1-Day Range:

$180.50

$189.18

1-Week Range:

$176.48

$189.18

52-Week Range:

$166.87

$275.00

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name

Charles River Laboratories International Inc

Sector

Healthcare (1182)

Industry

Diagnostics & Research (57)

Phone

781-222-6000

Address

251 BALLARDVALE ST, WILMINGTON, MA

Employee

Twitter

@criverlabs

Next Earnings Date

2024-11-06

Latest SEC Filings

CRL's Discussions on Twitter

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Sep-13-23	Initiated	TD Cowen	Market Perform
Jul-10-23	Downgrade	Citigroup	Buy → Neutral
Feb-23-23	Upgrade	Guggenheim	Neutral → Buy
Jan-12-23	Downgrade	Jefferies	Buy → Hold
Sep-30-22	Upgrade	Jefferies	Hold → Buy
Aug-25-22	Initiated	Credit Suisse	Outperform
Aug-04-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-24-22	Initiated	Guggenheim	Neutral
Apr-25-22	Downgrade	Jefferies	Buy → Hold
Apr-07-22	Initiated	Stephens	Overweight
Feb-17-22	Reiterated	BofA Securities	Buy
Feb-17-22	Upgrade	Citigroup	Neutral → Buy
Feb-17-22	Reiterated	Deutsche Bank	Buy
Feb-17-22	Reiterated	Morgan Stanley	Overweight
Feb-17-22	Reiterated	UBS	Buy
Aug-05-21	Resumed	Credit Suisse	Neutral
Dec-16-20	Downgrade	Citigroup	Buy → Neutral
Sep-10-20	Upgrade	Jefferies	Hold → Buy
Jul-01-20	Upgrade	BofA Securities	Neutral → Buy
May-13-20	Upgrade	UBS	Neutral → Buy
Apr-21-20	Downgrade	Jefferies	Buy → Hold
Mar-27-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-02-20	Initiated	Deutsche Bank	Buy
Feb-18-20	Upgrade	Wolfe Research	Peer Perform → Outperform
Jan-10-20	Upgrade	Goldman	Neutral → Buy
Jan-08-20	Initiated	Wells Fargo	Overweight
Jan-07-20	Initiated	Citigroup	Buy
Oct-18-19	Downgrade	BofA/Merrill	Buy → Neutral
Jun-10-19	Initiated	SVB Leerink	Outperform
Apr-30-19	Resumed	Evercore ISI	Outperform
Dec-14-18	Initiated	Deutsche Bank	Buy
Oct-09-18	Initiated	UBS	Neutral
Aug-23-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jul-17-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jun-15-18	Upgrade	KeyBanc Capital Mkts	Sector Weight → Overweight
Feb-14-18	Upgrade	SunTrust	Hold → Buy

View All

Charles River Laboratories International Inc Stock (CRL) Latest News

11:37 AM

Charles River Laboratories Q3 2024 Earnings Preview - MSN

11:37 AM

04:13 AM

Stephens Inc. AR Raises Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat

04:13 AM

03:55 AM

Cell Banking Outsourcing Market Report: Detailed Insights - openPR

03:55 AM

Nov 04, 2024

Gear Up for Charles River (CRL) Q3 Earnings: Wall Street Estimates for Key Metrics - Yahoo Finance

Nov 04, 2024

abrdn plc Decreases Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat

Nov 04, 2024

Gmp Cell Banking Services Market Size, Share, and Forecast - openPR

Nov 04, 2024

Nov 03, 2024

Restructuring update likely in Charles River Labs’ Q3 earnings - The Business Journals

Nov 03, 2024

Nov 01, 2024

Charles River Laboratories International, Inc. (NYSE:CRL) Short Interest Update - MarketBeat

Nov 01, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Nov 01, 2024

Oct 31, 2024

Zacks Research Has Weak Forecast for CRL FY2024 Earnings - MarketBeat

Oct 31, 2024

Congress Asset Management Co. Sells 9,239 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat

Oct 31, 2024

Oct 30, 2024

Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Oct 30, 2024

WD Rutherford LLC Has $338,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat

Oct 30, 2024

Charles River Laboratories International (CRL) to Release Earnings on Wednesday - MarketBeat

Oct 30, 2024

Charles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Rating of "Reduce" by Analysts - MarketBeat

Oct 30, 2024

Oct 29, 2024

Fragment Based Drug Discovery Market Size Projected to Achieve USD 2.1 Billion by 2031, Expanding at a 11.5% CAGR | Analysis by Transparency Market Research, Inc. - GlobeNewswire Inc.

Oct 29, 2024

Why Charles River (CRL) is Poised to Beat Earnings Estimates Again - Zacks Investment Research

Oct 29, 2024

Oct 28, 2024

Assenagon Asset Management S.A. Acquires 29,621 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat

Oct 28, 2024

Oct 27, 2024

Ophthalmic Clinical Trials Market Intelligence Reports - openPR

Oct 27, 2024

Boston Trust Walden Corp Decreases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat

Oct 27, 2024

Oct 26, 2024

Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet - Simply Wall St

Oct 26, 2024

Oct 25, 2024

Dumont & Blake Investment Advisors LLC Sells 4,360 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat

Oct 25, 2024

Oct 23, 2024

CLSA Begins Coverage on Charles River Laboratories International (NYSE:CRL) - MarketBeat

Oct 23, 2024

Oct 22, 2024

Charles River Laboratories International (NYSE:CRL) Trading Down 4.9%Should You Sell? - MarketBeat

Oct 22, 2024